Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2011

01-04-2011 | Original Article

The Expression of Both Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 in Tissues Is Associated with Poor Prognosis in Colorectal Cancer Patients

Authors: Masahiro Yoshinaga, Kentaro Taki, Shinichi Somada, Yumiko Sakiyama, Norihiko Kubo, Toyoma Kaku, Satoru Tsuruta, Tetsuya Kusumoto, Hironori Sakai, Kazuhiko Nakamura, Ryoichi Takayanagi, Yoichi Muto

Published in: Digestive Diseases and Sciences | Issue 4/2011

Login to get access

Abstract

Background

The role of peroxisome proliferator-activated receptor delta (PPAR δ) in the development and progression of colorectal cancer (CRC) remains controversial.

Aims

We investigated the impact of PPAR δ expression in tissues on liver metastasis of CRC.

Methods

We analyzed samples of primary CRC and matched normal adjacent tissues from 52 patients for the expression of PPAR δ, cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF)-A, and CXC chemokine receptor 4 (CXCR4). Correlations of the molecules expressions with clinical characteristics and prognosis of patients were studied.

Results

The number of patients positive for PPAR δ, COX-2, CXCR4, and VEGF-A was 25, 33, 18, and 19, respectively. Among the PPAR δ (+)/COX-2 (+), PPAR δ (−)/COX-2 (+), PPAR δ (+)/COX-2 (−), and PPAR δ (−)/COX-2 (−) patient groups, PPAR δ (+)/COX-2 (+) patients had the highest incidence of liver metastasis (p < 0.01). PPAR δ (+)/COX-2 (+) expression was a significant independent prognostic factor (HR = 7.108, 95% CI 1.231–41.029, p = 0.0283) by Cox proportional analysis. PPAR δ (+)/COX-2 (+) patients had the highest positivity for CXCR4 or VEGF-A in tissues (p < 0.01). Among the patients in the CXCR4 (+)/VEGF-A (+), CXCR4 (+)/VEGF-A (−), CXCR4 (−)/VEGF-A (+), and CXCR4 (−)/VEGF-A (−) groups, CXCR4 (+)/VEGF-A (+) patients had the highest incidence of liver metastasis (p < 0.01).

Conclusions

The expression of both PPAR δ and COX-2 in tissues may lead to liver metastasis and consequent poor prognosis in CRC patients.
Literature
1.
go back to reference Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–572.PubMedCrossRef Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–572.PubMedCrossRef
2.
go back to reference Yeatman TJ, Nicolson GL. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol. 1993;9:256–263.PubMed Yeatman TJ, Nicolson GL. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol. 1993;9:256–263.PubMed
3.
go back to reference Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767.PubMedCrossRef Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767.PubMedCrossRef
4.
go back to reference Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355–7359.PubMedCrossRef Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355–7359.PubMedCrossRef
5.
go back to reference Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-d attenuates colon carcinogenesis. Nat Med. 2004;10:481–483.PubMedCrossRef Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-d attenuates colon carcinogenesis. Nat Med. 2004;10:481–483.PubMedCrossRef
6.
go back to reference Reed KR, Sansom OJ, Hayes AJ, et al. PPAR δ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene. 2004;23:8992–8996.PubMedCrossRef Reed KR, Sansom OJ, Hayes AJ, et al. PPAR δ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene. 2004;23:8992–8996.PubMedCrossRef
7.
go back to reference Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARd decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 2001;98:2598–2603.PubMedCrossRef Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARd decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 2001;98:2598–2603.PubMedCrossRef
8.
go back to reference He TC, Chan TA, Vogelstein B, Kinzler KW. PPARd is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335–345.PubMedCrossRef He TC, Chan TA, Vogelstein B, Kinzler KW. PPARd is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335–345.PubMedCrossRef
9.
go back to reference Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-d accelerates intestinal adenoma growth. Nat Med. 2004;10:245–247.PubMedCrossRef Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-d accelerates intestinal adenoma growth. Nat Med. 2004;10:245–247.PubMedCrossRef
10.
go back to reference Takayama O, Yamamoto H, Damdinsuren B, et al. Expression of PPARd in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer. 2006;95:889–895.PubMedCrossRef Takayama O, Yamamoto H, Damdinsuren B, et al. Expression of PPARd in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer. 2006;95:889–895.PubMedCrossRef
11.
go back to reference Zuo X, Peng Z, Moussalli MJ, et al. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst. 2009;101:762–767.PubMedCrossRef Zuo X, Peng Z, Moussalli MJ, et al. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst. 2009;101:762–767.PubMedCrossRef
12.
go back to reference Nakamoto H, Uetake H, Iida S, et al. Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol. 2007;37(9):679–685.PubMedCrossRef Nakamoto H, Uetake H, Iida S, et al. Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol. 2007;37(9):679–685.PubMedCrossRef
13.
go back to reference Cascinu Stefano, Staccioli MariaPia, Gasparini Giampietro, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803–2807.PubMed Cascinu Stefano, Staccioli MariaPia, Gasparini Giampietro, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803–2807.PubMed
14.
go back to reference Ottaiano A, Franco R, Talamanca AA, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 2006;12:2795–2803.PubMedCrossRef Ottaiano A, Franco R, Talamanca AA, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 2006;12:2795–2803.PubMedCrossRef
15.
go back to reference Cutler NS, Graves-Deal R, LaFleur BJ, et al. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003;63:1748–1751.PubMed Cutler NS, Graves-Deal R, LaFleur BJ, et al. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003;63:1748–1751.PubMed
16.
go back to reference Wang D, Mann JR, DuBois RN. WNT and cyclooxygenase-2 crosstalk accelerates adenoma growth. Cell Cycle. 2004;3:1512–1515.PubMedCrossRef Wang D, Mann JR, DuBois RN. WNT and cyclooxygenase-2 crosstalk accelerates adenoma growth. Cell Cycle. 2004;3:1512–1515.PubMedCrossRef
17.
go back to reference Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004;6:285–295.PubMedCrossRef Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004;6:285–295.PubMedCrossRef
18.
go back to reference Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA. 2000;97:13275–13280.PubMedCrossRef Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA. 2000;97:13275–13280.PubMedCrossRef
19.
go back to reference Abdollahi A, Schwager C, Kleeff J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA. 2007;104:12890–12895.PubMedCrossRef Abdollahi A, Schwager C, Kleeff J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA. 2007;104:12890–12895.PubMedCrossRef
20.
go back to reference Ishizuka M, Sawada T, Okada T, et al. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery. J Invest Surg. 2009;22:105–111.PubMedCrossRef Ishizuka M, Sawada T, Okada T, et al. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery. J Invest Surg. 2009;22:105–111.PubMedCrossRef
21.
go back to reference Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003;5:R144–R150.PubMedCrossRef Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003;5:R144–R150.PubMedCrossRef
22.
go back to reference Uchida D, Begum NM, Almofti A, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003;290:289–302.PubMedCrossRef Uchida D, Begum NM, Almofti A, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003;290:289–302.PubMedCrossRef
23.
go back to reference Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–1750.PubMedCrossRef Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–1750.PubMedCrossRef
24.
go back to reference Gassmann P, Haier J, Schlüter K, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11:651–661.PubMed Gassmann P, Haier J, Schlüter K, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11:651–661.PubMed
25.
go back to reference Ohji Y, Yao T, Eguchi T, et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep. 2007;17:525–530.PubMed Ohji Y, Yao T, Eguchi T, et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep. 2007;17:525–530.PubMed
26.
go back to reference Zuo X, Wu Y, Morris JS, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006;25:1225–1241.PubMedCrossRef Zuo X, Wu Y, Morris JS, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006;25:1225–1241.PubMedCrossRef
27.
go back to reference Richard CL, Lowthers EL, Blay J. 15-Deoxy-delta(12, 14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways. Exp Cell Res. 2007;313:3446–3458.PubMedCrossRef Richard CL, Lowthers EL, Blay J. 15-Deoxy-delta(12, 14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways. Exp Cell Res. 2007;313:3446–3458.PubMedCrossRef
28.
go back to reference Richard CL, Blay J. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. Int J Oncol. 2007;30:1215–1222.PubMed Richard CL, Blay J. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. Int J Oncol. 2007;30:1215–1222.PubMed
29.
go back to reference Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPAR delta→gt;14–3-3 epsilon pathway. Methods Mol Biol. 2009;512:295–307.PubMedCrossRef Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPAR delta→gt;14–3-3 epsilon pathway. Methods Mol Biol. 2009;512:295–307.PubMedCrossRef
Metadata
Title
The Expression of Both Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 in Tissues Is Associated with Poor Prognosis in Colorectal Cancer Patients
Authors
Masahiro Yoshinaga
Kentaro Taki
Shinichi Somada
Yumiko Sakiyama
Norihiko Kubo
Toyoma Kaku
Satoru Tsuruta
Tetsuya Kusumoto
Hironori Sakai
Kazuhiko Nakamura
Ryoichi Takayanagi
Yoichi Muto
Publication date
01-04-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1389-9

Other articles of this Issue 4/2011

Digestive Diseases and Sciences 4/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.